# Pathos AI

> AI drug-development company using its Foundry platform to select clinical assets and guide its own therapeutic pipeline.

## Why it is interesting

Bristol Myers Squibb led Pathos's $237M Series E, announced October 23, 2026 at an approximately $3B post-money valuation, while entering a platform partnership. A separate Tempus agreement provides neurological data for fees of up to $55M over five years; these payments are not financing into Pathos.

## Profile

- **Latest funding:** Series E — $237M (October 23, 2026)
- **Latest known valuation:** Approximately $3B post-money (October 23, 2026)
- **Total disclosed equity funding:** $664M
- **Stage:** growth
- **Status:** private
- **Industries:** ai-ml, biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-10-23
- **Latest funding investors:** Bristol Myers Squibb, Unnamed existing investors

## Key facts

- October 23, 2026: closed $237M Series E led by Bristol Myers Squibb.
- Approximately $3B post-money valuation disclosed by the company.
- JSKN016 was developed by Alphamab and licensed by Pathos; it was not invented by Pathos's AI.
- Funding history lists individually documented Series C, D and E rounds. The company reported $102M cumulative funding in October 2024; earlier financing was not itemized in that announcement.

## Funding history

- Series E · $237M · October 23, 2026
  Source: https://www.pathos.com/pathos-ai-secures-237-million-in-series-e-financing-to-scale-agentic-ai-drug-development-platform-and-advance-oncology-pipeline
- Series D · $365M · May 15, 2025
  Source: https://www.pathos.com/pathos-ai-secures-365-million-in-series-d-financing-to-advance-oncology-drug-development-through-ai
- Series C · $62M · October 29, 2024
  Source: https://www.pathos.com/pathos-ai-closes-62m-oversubscribed-series-c-round-of-financing-to-accelerate-its-platform-approach-to-drug-development

## Investors in our directory

- https://venturecapitaltracker.com/fund/new-enterprise-associates
- https://venturecapitaltracker.com/fund/lightbank

## Related articles

- https://venturecapitaltracker.com/pathos-ai-237m-series-e-3b-valuation

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** October 23, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/pathos-ai